Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Glaxo Pen SNP-Marker Collaboration

NEW YORK, Sept. 19 - Illumina and GlaxoSmithKline will turn a "large" set of SNP markers into SNP assays that Illumina will use to create a whole-genome linkage disequilibrium-mapping product to be deployed with its BeadArray platform, the companies said today.

 

Meantime, Glaxo will use the platform to genotype patient samples and disease populations, and will evaluate the use of high-density SNP-evaluation studies in the search for disease loci, according to Illumina.

 

The partners will co-create "performance criteria," evaluate candidate SNP markers, and select an "extensive" set for assay development. Illumina said the assay development will take place "over several month."

 

Click here for more information.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.